The Time is NOW
2.0
Unither 2.0 2016
UNITHER 2.0
OWNER'S MANUAL
QUICK
START
GUIDE
2.0
UNITHER 2.0 VERSION 2016
UNITED THERAPEUTICS CORPORATION

UNITHER 2.0

OWNER'S MANUAL

QUICK START GUIDE



Introducing Unither 2.0

Congratulations on your investment in **Unither 2.0**

Unither 2.0 is a comprehensive performance organization incorporating inspiration, passion, hard work, persistence, dedication and a relentless pursuit of innovation to provide a better than ever biotech for an ever more demanding healthcare environment.

This guide reflects the latest instructions for **Unither 2.0** and will allow you to use all of the features of **Unither 2.0** for yourself and on behalf of our patients, our shareholders and all of our other stakeholders.

You will find **Unither 2.0** to be a user-friendly biotech innovation machine. But like any new machine, you should take the time to familiarize yourself with all of its features in order to optimize its performance.

Unither 2.0 – Double Down, Double Time



Dear Unither 2.0 Owners,

Unither 2.0 means everything at United Therapeutics is moving faster and better than previously. We are no longer just about more advanced treatments for end-stage lung disease; we are here to *cure* diseases affecting vital organs with an unlimited supply of manufactured, well-tolerated organs.

When we turned 20 years old on June 26, 2016 we decided to move the decimal one place to the left. By doing so we rebirthed ourselves as a company whose clinical development timelines moved to the left. What previously would take us over five years to bring to market – such as Orenitram for Pulmonary Arterial Hypertension – we would now bring to market in five years or less, as we are aiming to do with Orenitram for Heart Failure with Preserved Ejection Fraction.

By moving our decimal one place to the left we also signified that we were moving time to peak revenues to the left. While it took United Therapeutics 14 years to reach its



current peak revenues of about $1.6 billion, we are aiming to bring on line the next $1.6 billion in under seven years. This revenue growth should be made possible by several technological innovations which make life better for patients:

> ***Remopro***, our meticulously created new chemical entity form of the active pharmaceutical ingredient in Remodulin, is aiming to be the holy grail of parenteral pulmonary hypertension therapy by avoiding both intravenous lines and the site pain of subcutaneous infusions. We are hoping this therapy will both double the number of years patients spend on parenteral therapy, and double the number of patients willing to use such therapy.
>
> ***Tysuberprost***, the first ever therapeutic protocol to attack pulmonary hypertension from both the airway and blood sides, is expected to enable patients to remain on inhaled pulmonary hypertension therapy for twice as long as previously. This will be such a tremendous boon to patients that we think we can double the peak number of patients on inhaled therapy.



Disciplined pursuit of less but better

Dinutuximab, our monoclonal antibody against tumor cells expressing the GD-2 antigen, is now being tested against small cell lung cancer in a Phase 3 trial at over 200 hospitals. While it took about a decade to get this biologic used by about 1,000 patients for neuroblastoma, we expect our humanized form to be used by more than twice as many patients, and within fewer years, for multiple cancers.

Every time we say to each other **"Unither 2.0"**, we are saying "how can we move this project or product to the left," i.e., *let's figure out how we do it better and faster*. We are cognizant that patients and their families need our treatments sooner, and that shareholders want business execution times accelerated. For example, within the past year we've doubled down on our lung organ manufacturing expertise with parallel efforts at kidney and heart manufacturing as well.

Like ever-better software, **Unither 2.0** is a better than ever organization for an ever more demanding healthcare environment.

MAR

Martine A. Rothblatt
Chairman and Soul CEO



2016 Performance Mode

- All-time high annual revenues – $1.6 billion
- All-time high non-GAAP earnings – $748.6 million
- All-time high net income – $713.7 million
- Continued growth in our newest products Orenitram® and Unituxin®
- Launched numerous R&D programs to develop new therapies and expanded use of our existing products
- Undertaking *seven* simultaneous pivotal clinical trials, a record for United Therapeutics
- Revenues have grown by approximately 9% or more in 15 consecutive years
- Over the last 15 years, our stock price has grown at an annual growth rate that is twice that of the NASDAQ Biotechnology Index
- Cumulatively, our stock price growth is six times that of the NASDAQ Biotechnology Index
- In the last five years, we have returned over $1.8 billion to our shareholders through stock repurchases representing approximately 25% of our current outstanding shares, including $500 million in stock repurchases during 2016

Unlimited Supply of Transplantable Organs Manufacturing Mode

- **Each Year, Millions Of People Die From End-Stage Organ Failure, A Significant Number of These Patients Could Have Benefitted From An Organ Transplant –** Yet the number of usable, donated organs available for transplantation has not changed significantly over the past half century while the need has soared
- **We Believe Organ Shortage Is Something We Can Do Something About –** With advances in technology, creating an unlimited supply of tolerable manufactured organs is now principally an engineering challenge and we are dedicated to engineering solutions
- **Since 2011 We Have Been Engaged In Creating An Unlimited Supply of Tolerable Transplantable Organs –** Our manufactured lungs, kidneys and hearts have set records for viability
- **We are Pursuing Our Goals Through Multiple Technologies And Development Programs –** Multiple shots on goal, the United Therapeutics way

- **Manufactured Organs Will Save The Health Care Systems Many Times Their Cost –** Avoiding the huge hospitalization expenses associated with end-stage kidney, heart and lung failure
- **We View Organ Manufacturing As The Ultimate Technology Solution For A Broad Array Of Diseases –** Turning science fiction into science fact to extend human longevity through a paradigm of abundance in the field of transplantation science



Public Benefit Corporation Mode

- **Our Subsidiary Lung Biotechnology PBC Is A Public Benefit Corporation –** a new corporate for-profit form that requires it to be managed in a manner that balances *both* the shareholders' financial interests *and* the public benefit identified in its Articles of Incorporation
- **Lung Biotechnology PBC Is The First PBC Subsidiary of A Public Biotechnology Or Pharmaceutical Company In The U.S. –** An innovation in corporate form to match our innovation in technology development
- **Lung Biotechnology PBC's Public Benefit Purpose Is:**
  "To address the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply"
- **Our Board And Management Are Required To Run Lung Biotechnology PBC For Both This Public Benefit As Well As Conventional Stockholder Value –** Our manufactured organ and regenerative medicine businesses are all managed in Lung Biotechnology PBC
- **Saving Lives Is The Ultimate Public Benefit –** When we take care of our patients, our shareholders also benefit

United Therapeutics Mode

United Therapeutics Is The Most Revolutionary Company In Human Longevity – United Therapeutics is the only company on track to extend EVERYONE's life with replacement hearts, lungs and kidneys

United Therapeutics Is The Most Innovative Company In Cardiopulmonary Medicine – United Therapeutics is the only company that pharmacogenomically sequences all new patients in its clinical trials

United Therapeutics Is The Most Important Company In Pulmonary Hypertension – United Therapeutics helps more patients with pulmonary hypertension in the USA than any other company

At United Therapeutics, Our Tag Line Is *Medicines for Life* Because Our Development Pathway Is The Practical Pathway For Greater Human Longevity

Commerical Products Mode

REMODULIN®
(treprostinil) Injection

adcirca®
tadalafil tablets 20mg

TYVASO
(treprostinil) INHALATION SOLUTION

Unituxin®
(dinutuximab)
Injection

orenitram®
treprostinil

Nearer-Term Pipeline Mode



Medium-Term Pipeline Mode



17

Longer-Term Pipeline Mode



Unither 2.0 Care and Maintenance



Function:
1. 5x17 LED display, showing time and phases.
2. Operation: LED closed normally; Press the key, show time and phases one by one. Each phases or time show 5seconds max. Then quit if not touch the key.
3. Total 4 Phases, pressing key to choose. "UTHR 2.0", "NOW","WATCH US GROW", "LET'S GO !" Scroll display from right to left
4. Time setting: In time interface, hold the key 3secons. The number flashing in the display.

Press 1time, go to "12Hours system"; press again, go to "24Hours system";
Hold the key 2 seconds again, turning to "Hour" changing system;
Hold the key 2 seconds, altering "Minutes".
After operation, 5seconds later, return standby model.

Declaration of Conformity

(according to USA Guide 22 and EB 45014)

Manufacturers Name: United Therapeutics Corporation

Manufacturer's Address: 1040 Spring Street
Silver Spring, MD 20910

55 T.W. Alexander Drive
Research Triangle Park, NC 27709

Declares that Unither 2.0 conforms to United Therapeutics' 3X4 Twelve-Year Business Plan.

Christopher Causey
Raymond Dwek
Richard Giltner
Katherine Klein
Raymond Kurzweil
Judy D. Olian
Christopher Patusky
Martine A. Rothblatt
Louis W. Sullivan
Tommy Thompson

Date: June 26, 2017



FASTEN YOUR SEATBELTS
FOLKS!

Unither 2.0

Double Down, Double Time

NASDAQ/UTHR 626UT-34UT-119UT-1201E BDR529

LAB 4